MA27729A1 - Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre - Google Patents

Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Info

Publication number
MA27729A1
MA27729A1 MA28560A MA28560A MA27729A1 MA 27729 A1 MA27729 A1 MA 27729A1 MA 28560 A MA28560 A MA 28560A MA 28560 A MA28560 A MA 28560A MA 27729 A1 MA27729 A1 MA 27729A1
Authority
MA
Morocco
Prior art keywords
receptor agonist
sugar alcohol
solid pharmaceutical
pharmaceutical compositions
compositions containing
Prior art date
Application number
MA28560A
Other languages
English (en)
French (fr)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27729(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Pharma Corp filed Critical Novartis Ag
Publication of MA27729A1 publication Critical patent/MA27729A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA28560A 2003-04-08 2005-10-19 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre MA27729A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
MA27729A1 true MA27729A1 (fr) 2006-01-02

Family

ID=32326722

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28560A MA27729A1 (fr) 2003-04-08 2005-10-19 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Country Status (41)

Country Link
US (11) US20060275357A1 (h)
EP (5) EP2769713A1 (h)
JP (3) JP5495467B2 (h)
KR (3) KR20050121712A (h)
CN (2) CN1767819B (h)
AR (3) AR043987A1 (h)
AT (3) ATE414508T1 (h)
AU (1) AU2004228929B2 (h)
BE (2) BE1015972A5 (h)
BR (1) BRPI0409250B8 (h)
CA (2) CA2707750A1 (h)
CL (2) CL2004000745A1 (h)
CY (3) CY1110260T1 (h)
DE (4) DE122011100047I1 (h)
DK (2) DK2316431T3 (h)
EC (1) ECSP056090A (h)
ES (3) ES2228282B1 (h)
FR (2) FR2854073B1 (h)
GB (1) GB2400318B (h)
GR (1) GR1005052B (h)
HR (3) HRP20050886B1 (h)
HU (2) HUE028247T2 (h)
IL (3) IL170888A (h)
IS (2) IS2682B (h)
IT (1) ITMI20040682A1 (h)
LU (1) LU91867I2 (h)
MA (1) MA27729A1 (h)
MX (1) MXPA05010860A (h)
MY (1) MY141249A (h)
NO (4) NO329332B1 (h)
NZ (3) NZ542622A (h)
PE (5) PE20090743A1 (h)
PL (2) PL2316431T3 (h)
PT (1) PT1613288E (h)
RU (5) RU2358716C2 (h)
SG (1) SG175449A1 (h)
SI (2) SI2316431T1 (h)
TN (1) TNSN05256A1 (h)
TW (1) TWI332847B (h)
WO (1) WO2004089341A1 (h)
ZA (1) ZA200507394B (h)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527055T3 (es) * 2004-07-30 2015-01-20 Novartis Ag Formulaciones de compuestos 2-amino-1,3-propanodiol
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
CA2620554C (en) * 2005-09-09 2013-12-17 Novartis Ag Treatment of autoimmune diseases
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ603303A (en) 2006-06-19 2014-05-30 Onyx Therapeutics Inc Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
HUE046441T2 (hu) * 2006-09-26 2020-02-28 Novartis Ag S1P modulátort tartalmazó gyógyászati készítmények
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
PT2140867T (pt) * 2007-03-29 2017-10-04 Daiichi Sankyo Co Ltd Composição farmacêutica
TWI501773B (zh) 2007-10-04 2015-10-01 Onyx Therapeutics Inc 結晶肽環氧酮蛋白酶抑制劑以及胺基酸酮環氧化物之合成
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
EP2653154A1 (en) 2007-10-12 2013-10-23 Novartis AG Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
SI2278960T2 (sl) 2008-03-17 2020-02-28 Actelion Pharmaceuticals Ltd. Režim odmerjanja za selektivni agonist receptorja sip1
TR201808694T4 (tr) * 2008-06-20 2018-07-23 Merck Patent Gmbh Doğrudan sıkıştırılabilen ve hızlı parçalanan tablet matrisi.
CA2728514C (en) 2008-06-20 2020-08-11 Novartis Ag Paediatric compositions for treating multiple sclerosis
CN102143692A (zh) * 2008-09-04 2011-08-03 卡吉尔公司 赤藓醇的压片
CA2741312C (en) 2008-10-21 2020-10-27 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
CA2743232C (en) * 2008-11-11 2015-12-29 Novartis Ag Crystalline forms of fingolimod hcl
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
JP5305421B2 (ja) 2008-12-17 2013-10-02 第一三共株式会社 ジアミン誘導体の製造方法
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd ACTIVE BLOOD CREATION FACTOR HEMMER
WO2010104078A1 (ja) 2009-03-10 2010-09-16 第一三共株式会社 ジアミン誘導体の製造方法
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
KR20120037396A (ko) * 2009-06-18 2012-04-19 다이이찌 산쿄 가부시키가이샤 용출성이 개선된 의약 조성물
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
JP6042724B2 (ja) 2010-03-01 2016-12-14 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． イムノプロテアソーム阻害のための化合物
WO2011115066A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
WO2011115067A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 抗凝固剤の溶出改善方法
WO2011131368A2 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
EP2589590B1 (en) 2010-07-02 2016-12-28 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
PT2661261T (pt) 2011-01-07 2019-10-25 Novartis Ag Formulações imunossupressoras.
NO2665471T3 (h) 2011-01-19 2018-05-26
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
EP2739272A1 (en) * 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
CA2844604C (en) 2011-08-10 2017-07-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ethanediamide derivatives
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CN105163730B (zh) 2013-01-08 2018-10-30 帕萨罗杰卡有限公司 用于治疗脱髓鞘疾病的方法和组合物
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2990055B1 (en) * 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
ES2770500T3 (es) * 2013-05-13 2020-07-01 Synthon Bv Composición farmacéutica que comprende fingolimod
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
EP4181906A1 (en) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
EP4438037A1 (en) * 2021-01-28 2024-10-02 Priothera SAS Methods of treatment with s1p receptor modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
CA2126337C (en) 1992-10-21 2003-06-24 Tetsuro Fujita 2-amino-1,3-propanediol compound and immunosuppressant
JP3870419B2 (ja) 1994-08-22 2007-01-17 三菱ウェルファーマ株式会社 ベンゼン化合物およびその医薬としての用途
CZ285953B6 (cs) 1995-12-28 1999-12-15 Yoshitomi Pharmaceutical Industries, Ltd. Vnější přípravek pro topické podání
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
CA2282378C (en) * 1997-02-27 2008-12-30 Yoshitomi Pharmaceutical Industries Ltd. Pharmaceutical composition
ATE271028T1 (de) * 1997-04-04 2004-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
AU6950301A (en) 2000-07-13 2002-01-30 Sankyo Co Amino alcohol derivatives
JP2004507552A (ja) * 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
KR20030093279A (ko) 2001-03-26 2003-12-06 노파르티스 아게 2-아미노-프로판올 유도체
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
EP1424078A4 (en) 2001-09-04 2009-03-25 Ono Pharmaceutical Co RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT
WO2003029205A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
AU2003216054B2 (en) 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
WO2003062392A2 (en) 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor
EP1470137B1 (en) 2002-01-18 2009-09-02 Merck & Co., Inc. Edg receptor agonists
RU2396982C2 (ru) * 2004-07-16 2010-08-20 Киорин Фармасьютикал Ко., Лтд. Эффективный способ использования лекарственных средств и способ предотвращения выраженности побочных эффектов

Also Published As

Publication number Publication date
KR20050121712A (ko) 2005-12-27
RU2010147000A (ru) 2012-08-10
CY2011013I2 (el) 2014-04-09
AR078781A2 (es) 2011-11-30
AT501681A1 (de) 2006-10-15
BE2011C030I2 (h) 2023-03-07
HK1091114A1 (en) 2007-01-12
PL1613288T3 (pl) 2009-07-31
EP2316431B1 (en) 2015-09-30
FR2854073B1 (fr) 2008-03-14
IL197578A (en) 2015-10-29
GB2400318B (en) 2005-08-10
NO335120B1 (no) 2014-09-22
PE20150676A1 (es) 2015-05-17
DE122011100047I1 (de) 2011-12-15
RU2475236C2 (ru) 2013-02-20
US20190175527A1 (en) 2019-06-13
CL2004000745A1 (es) 2005-02-11
MXPA05010860A (es) 2006-05-25
AT501681B1 (de) 2012-04-15
NZ586280A (en) 2011-12-22
NO20131287L (no) 2006-01-09
RU2475237C2 (ru) 2013-02-20
EP2769713A1 (en) 2014-08-27
WO2004089341A1 (en) 2004-10-21
SG175449A1 (en) 2011-11-28
US20090203798A1 (en) 2009-08-13
IS8114A (is) 2005-11-01
TW200503784A (en) 2005-02-01
DE102004016947A1 (de) 2004-10-21
US20140011885A1 (en) 2014-01-09
LU91867I2 (fr) 2011-11-08
TNSN05256A1 (en) 2007-07-10
IL242037A0 (en) 2015-11-30
US20220031609A1 (en) 2022-02-03
NZ592339A (en) 2012-09-28
RU2009105403A (ru) 2010-08-27
DK1613288T3 (da) 2009-03-23
HK1155647A1 (en) 2012-05-25
IL170888A (en) 2010-06-16
KR101367574B1 (ko) 2014-02-25
HRP20100601A2 (hr) 2011-03-31
ATE414508T1 (de) 2008-12-15
IE20040246A1 (en) 2004-12-15
US20080311188A1 (en) 2008-12-18
HUE028247T2 (en) 2016-12-28
HRP20100600A2 (hr) 2011-03-31
US20060275357A1 (en) 2006-12-07
PE20050396A1 (es) 2005-07-05
AU2004228929A1 (en) 2004-10-21
JP2011006461A (ja) 2011-01-13
FR2854073A1 (fr) 2004-10-29
GB2400318A (en) 2004-10-13
NO2011016I2 (no) 2012-08-27
EP2319502A1 (en) 2011-05-11
JP5543298B2 (ja) 2014-07-09
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
US20130108675A1 (en) 2013-05-02
CA2521325A1 (en) 2004-10-21
AT504853A2 (de) 2008-08-15
CN1767819B (zh) 2010-07-28
IS2682B (is) 2010-10-15
HUS1100016I1 (hu) 2016-08-29
BRPI0409250B1 (pt) 2017-07-11
US20110105620A1 (en) 2011-05-05
NZ542622A (en) 2009-01-31
NO329332B1 (no) 2010-09-27
EP1613288B1 (en) 2008-11-19
KR20110005320A (ko) 2011-01-17
EP1613288A1 (en) 2006-01-11
CN1767819A (zh) 2006-05-03
AU2004228929B2 (en) 2008-02-07
IL197578A0 (en) 2011-07-31
CA2707750A1 (en) 2004-10-21
FR11C0036I1 (fr) 2011-10-14
ES2320767T3 (es) 2009-05-28
EP2008650A3 (en) 2011-04-27
HRP20050886B1 (en) 2011-01-31
KR20120101148A (ko) 2012-09-12
PE20131352A1 (es) 2013-11-14
CA2521325C (en) 2010-09-14
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
MY141249A (en) 2010-03-31
CY2011013I1 (el) 2014-04-09
PE20130200A1 (es) 2013-03-09
AR043987A1 (es) 2005-08-17
BRPI0409250A (pt) 2006-03-28
SI2316431T1 (sl) 2016-04-29
NO20055231D0 (no) 2005-11-07
RU2010146697A (ru) 2012-05-27
ES2228282A1 (es) 2005-04-01
EP2008650A2 (en) 2008-12-31
NO2011016I1 (no) 2011-09-19
ES2228282B1 (es) 2006-02-16
US20200237690A1 (en) 2020-07-30
TWI332847B (en) 2010-11-11
GR20040100121A (el) 2004-12-17
IS8885A (is) 2010-02-25
JP5495467B2 (ja) 2014-05-21
SI1613288T1 (sl) 2009-04-30
FR11C0036I2 (fr) 2023-12-29
AR078782A2 (es) 2011-11-30
NO334116B1 (no) 2013-12-16
US20170290787A1 (en) 2017-10-12
JP2004307506A (ja) 2004-11-04
CY1110260T1 (el) 2014-04-09
US20140255497A1 (en) 2014-09-11
JP2013177404A (ja) 2013-09-09
RU2358716C2 (ru) 2009-06-20
LU91867I9 (h) 2019-01-03
PT1613288E (pt) 2009-02-25
CN101797241A (zh) 2010-08-11
HRP20100601B1 (hr) 2016-12-02
RU2005134173A (ru) 2006-09-10
GB0407819D0 (en) 2004-05-12
ITMI20040682A1 (it) 2004-07-06
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
HRP20050886A2 (en) 2006-11-30
DE602004017847D1 (de) 2009-01-02
ES2556947T3 (es) 2016-01-21
RU2012148593A (ru) 2014-05-20
ECSP056090A (es) 2006-03-01
NO20100250L (no) 2006-01-09
DK2316431T3 (en) 2016-01-11
PE20090743A1 (es) 2009-07-17
CY1117071T1 (el) 2017-04-05
GR1005052B (el) 2005-11-30
US8324283B2 (en) 2012-12-04
BRPI0409250B8 (pt) 2022-01-18
ZA200507394B (en) 2007-03-28
DE202004021680U1 (de) 2010-04-22

Similar Documents

Publication Publication Date Title
MA27729A1 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
TNSN08194A1 (fr) Compositions pharmaceutiques solides contenant de la pregabaline
MA30598B1 (fr) Composition pharmaceutique contenant un acide tetrahydrofolique.
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA30766B1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
ES2181055T3 (es) Formulaciones galenicas que contienen antagonistas de opiaceos.
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
MA30999B1 (fr) Composés.
MA27668A1 (fr) 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
DZ2549A1 (fr) Compositions pharmaceutiques contenant de l&#39;hémisulfate d&#39;élétriptan.
PL415001A1 (pl) Kompozycje farmaceutyczne zawierające kwas mykofenolowy lub sól mykofenolanową
EP1750862A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
MA26964A1 (fr) Association d&#39;agonistes de gaba et d&#39;inhibiteurs de sorbitol-deshydrogenase.
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
BR0215148A (pt) Composições farmacêuticas de agonista parcial 5ht4
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
NO20064808L (no) Orale matrixformuleringer med licarbazepin
MA30691B1 (fr) Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l&#39;aluminium.
MY142076A (en) Emulsifying systems containing azetidine derivatives
CA2204475A1 (fr) Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение